Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy

León, Xavier; Agüero, Adriana; López, Montserrat; Garcı́a, Jacinto; Farré, Núria; López‐Pousa, Antonio; Quer, Miquel

doi:10.1016/j.anl.2014.10.002

Cited by 19 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with recurrent HNSCC after nonsurgical organ‐preservation treatment represent a challenge for the head and neck multidisciplinary team. Several studies have documented an increased number of postoperative complications after treatment with organ‐preservation therapy, ranging from 23% to 86% (Table ) . Those patients also exhibit lower survival rates, longer hospitalization, and high economic costs …”

Section: Introductionmentioning

confidence: 99%

Salvage surgery after head and neck squamous cell carcinoma treated with bioradiotherapy

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Salvage surgery after head and neck squamous cell carcinoma treated with bioradiotherapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…León et al [18] analyzed the response to and the surgical complications of rescue surgery after CRT ( n = 154) or BRT ( n = 33). BRT patients were older and had more comorbidities.…”

Section: Resultsmentioning

confidence: 99%

Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab

Granados-García

Aguilar-Ponce²,

Maldonado-Magos³

et al. 2016

ORL

View full text Add to dashboard Cite

We review clinical trials of squamous cell carcinoma of the head and neck (SCCHN) to address the current and potential uses of cetuximab (CTX). PubMed was reviewed to identify papers published between 2010 and 2016. The search terms used were “cetuximab” and “head and neck cancer.” A total of 634 articles were identified. Phase II or III studies with CTX in patients with advanced SCCHN without treatment or with recurrent/metastatic tumors were selected. Forty-six registries were obtained. Information was critically reviewed and relevant information presented. As definitive treatment of advanced squamous cells carcinomas and as palliative treatment of recurrent/metastatic disease, CTX alone or associated with chemotherapy and/or radiotherapy is an alternative to chemoradiotherapy because of its distinct and favorable toxicity profile.

show abstract

“…Lefebvre,et al 13 showed that rescue surgery was possible only in patients undergoing CTX/RT after induction CT. León, et al 50 recorded the clinical response and surgical complications after rescue surgery due to relapse after CTRT (n = 154) or CTX/RT (n = 33). The CTX/RT-treated patients had higher mean age and ECOG with regard to CTRT-treated patients; 37.2% of patients with CTRT and 61.5% with CTX/RT underwent rescue surgery.…”

Section: During Ctx/rtmentioning

confidence: 99%

Multidisciplinary, Multi-Institutional Consensus on Cetuximab Usefulness in the Treatment of Patients with Head and Neck Squamous Cell Carcinoma

Barrera-Franco¹,

Bautista-Aragón²,

Gallegos-Hernández³

et al. 2022

GAMO

View full text Add to dashboard Cite

Epidermal growth factor receptor is preferably expressed in head and neck squamous cell carcinomas and is a promising therapeutic target. Cetuximab is the only epidermal growth factor receptor-targeted agent that has been approved for the treatment of squamous cell carcinoma. The 2006 FDA-approved indication refers to the use of cetuximab in combination with radiotherapy for the treatment of locoregional, advanced, unresectable head and neck squamous cell carcinoma, except for nasopharyngeal carcinoma. In 2011, the use of cetuximab in combination with platinum and 5-fluorouracil was approved as first-line treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. In order to homogenize and arrive at a multidisciplinary, multi-institutional consensus based on scientific evidence, a meeting was held where the existing literature was reviewed and the role of cetuximab in the treatment of patients with head and neck squamous cell carcinoma was discussed. This work reviews current evidence-based indications for the use of cetuximab in the treatment of patients with head and neck squamous cell carcinoma. (creativecommons.org/ licenses/by-nc-nd/4.0/).

show abstract

Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy

Cited by 19 publications

References 23 publications

Salvage surgery after head and neck squamous cell carcinoma treated with bioradiotherapy

Salvage surgery after head and neck squamous cell carcinoma treated with bioradiotherapy

Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab

Multidisciplinary, Multi-Institutional Consensus on Cetuximab Usefulness in the Treatment of Patients with Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About